ERBB2 and neoplasm: Accordingly, in this study, we performed a successful in vivo analysis using trastuzumab, an inhibitor of HER2 with growing interest in EC clinical management,[26, 29, 30] after the identification of an actionable mutation (ERBB2R678Q) in the primary and the corresponding PDOX tumor.